Articles By Jack Cush, MD
Sustained Efficacy of Bimekizumab in Psoriatic Arthritis
BE OPTIMAL trial tested the benefits of a dual IL-17 A/F inhibitor, bimekizumab (BKZ), in patients with active psoriatic arthritis and showed superior efficacy over placebo, that was sustained beyond the primary endpoint, from week 16 to 52.
Read Article
SAPHYR Trial: Sarilumab Wins in Relapsing Polymyalgia Rheumatica
NEJM reported today that polymyalgia rheumatica (PMR) patients who fail to respond to standard doses of prednisone therapy, were significantly better when given the IL-6 inhibitor sarilumab (than placebo).
Read Article
Predictive FDG-PET in Newly Diagnosed GCA
Annals of Internal Medicine reports that the use of 18F-fluorodeoxyglucose (FDG) PET imaging at the time of a giant cell arteritis (GCA) diagnosis may help estimate the risk for aortic aneurysm formation.
Read Article
TNR: PMR Diagnosis and Monitoring
Panelists Dr. Claire Owen, Stephen Paget, Anisha Dua and Jack Cush discuss diagnosis and monitoring in PMR during this week's Tuesday Night Rheumatology.
Read Article
Gout Flare Prophylaxis - Colchicine or NSAIDs?
Flare prophylaxis is the standard when initiating urate-lowering therapy (ULT) in patients with gout. A new study suggests that colchicine, more so than non-steroidal anti-inflammatory drug (NSAID) prophylaxis, may increase the odds of adverse events, when initiating allopurinol for gout.
Read Article
October is PMR Month
PMR has come a long way from being an occasional referral and often test question, to now being a hot area of drug development and investigation. Led by numerous investigators and educators worldwide, there are new insights into the diagnosis, management and outcomes of PMR patients, with greater clarity on how and where it differs from giant cell arteritis.
Read Article
RheumNow Podcast – with Special Guest Dr. Kathryn Dao (9.29.2023)
This week on the podcast, Dr. Jack Cush is joined by special guest, Dr. Kathryn Dao to review the news and journal reports from the past week on RheumNow.com. They discuss unmet needs in gout, obesity and CV disease in PsA and should you check ANCA antibodies in SLE?
Read Article
Uncertainty on Pre-Clinical RA – Rheumatologist Survey Results
In June 2023, RheumNow surveyed US and non-US rheumatologists (Rheums) about how they consider and manage pre-clinical rheumatoid arthritis (RA) in their practice.
Read Article
Microvascular CV Disease with Severe Psoriasis
While comorbidities, including an increased cardiovascular (CV) risk, are associated with severe psoriasis, less is known about subclinical CV disease and when it occurs in patients with psoriasis.
Read Article
Advice on Multi-Drug Failures in RA
What’s your next best approach to the rheumatoid arthritis (RA) patient who has failed several DMARDs and biologics? In such cases you have to either reconsider the diagnosis (especially if seronegative) or reach into your bag of tricks.
Read Article
